EVGN vs. OMIC, SPRB, MRM, FEMY, PRE, VIRX, LEXX, NMTC, PLUR, and CASI
Should you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Singular Genomics Systems (OMIC), Spruce Biosciences (SPRB), MEDIROM Healthcare Technologies (MRM), Femasys (FEMY), Prenetics Global (PRE), Viracta Therapeutics (VIRX), Lexaria Bioscience (LEXX), NeuroOne Medical Technologies (NMTC), Pluri (PLUR), and CASI Pharmaceuticals (CASI). These companies are all part of the "medical" sector.
Evogene (NASDAQ:EVGN) and Singular Genomics Systems (NASDAQ:OMIC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
Evogene has higher revenue and earnings than Singular Genomics Systems. Evogene is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Evogene has a net margin of -423.39% compared to Singular Genomics Systems' net margin of -3,257.30%. Singular Genomics Systems' return on equity of -45.33% beat Evogene's return on equity.
Evogene presently has a consensus price target of $3.62, suggesting a potential upside of 478.57%. Singular Genomics Systems has a consensus price target of $0.68, suggesting a potential upside of 67.00%. Given Evogene's stronger consensus rating and higher probable upside, equities analysts plainly believe Evogene is more favorable than Singular Genomics Systems.
10.4% of Evogene shares are held by institutional investors. Comparatively, 65.8% of Singular Genomics Systems shares are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 21.9% of Singular Genomics Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Evogene has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Singular Genomics Systems has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
In the previous week, Evogene had 2 more articles in the media than Singular Genomics Systems. MarketBeat recorded 3 mentions for Evogene and 1 mentions for Singular Genomics Systems. Singular Genomics Systems' average media sentiment score of 0.57 beat Evogene's score of 0.56 indicating that Singular Genomics Systems is being referred to more favorably in the news media.
Evogene received 206 more outperform votes than Singular Genomics Systems when rated by MarketBeat users. Likewise, 60.00% of users gave Evogene an outperform vote while only 48.15% of users gave Singular Genomics Systems an outperform vote.
Summary
Evogene beats Singular Genomics Systems on 11 of the 18 factors compared between the two stocks.
Get Evogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
